RxDoctor Payments Data

Iqubal Dhaliwal, MD

Internal Medicine · Wrentham, MANPI 1770694556

Payments from drug & device makers

$5,774in general payments, 2019–2025

Across 27 payments — averaging $213.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$4K
  • Novo Nordisk$577
  • Abbott$221
  • Johnson & Johnson$127
  • Eisai Inc.$125
  • Lilly USA, LLC$124
  • plus $316 from 5 others

What the payments were for

  • Food & beverage$5,774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,774 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$323,565
Medicare patients
638
Services billed
4,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$223,788
JardianceEmpagliflozin94$122,967
OzempicSemaglutide47$52,868
OxycontinOxycodone Hcl37$34,246
TrulicityDulaglutide31$32,580
JanuviaSitagliptin Phosphate22$29,739
XareltoRivaroxaban72$28,229
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$28,079
Breo ElliptaFluticasone/Vilanterol49$27,806
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$27,279
Tresiba Flextouch U-200Insulin Degludec12$26,668
FarxigaDapagliflozin Propanediol32$25,563
Atorvastatin Calcium989$12,036
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,348
EntrestoSacubitril/Valsartan11$9,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Arexvy$64$76,569105 claims
Novo NordiskOzempic$577$52,86847 claims
Lilly USA, LLCTrulicity$124$32,58031 claims
Johnson & JohnsonXarelto$127$28,22972 claims
NovartisEntresto$118$9,64911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Wrentham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →